Journal article
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Abstract
OBJECTIVE: To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
RESEARCH DESIGN AND METHODS: Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior …
Authors
Kwan AYM; Gerstein HC; Basile J; Xavier D; Maldonado JM; Raha S; Konig M
Journal
Diabetes Care, Vol. 45, No. 3, pp. 547–554
Publisher
American Diabetes Association
Publication Date
March 1, 2022
DOI
10.2337/dc21-1160
ISSN
0149-5992